Trial intelligence / Profile preview

FIREFLY-2: tovorafenib versus standard chemotherapy for first-line pediatric low-grade glioma with RAF alteration

NL-OMON60059Phase 3Active, not recruiting

Sponsor

Day One Biopharmaceuticals

Start

Jul 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1